Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05201001Phase 2Withdrawn

APX005M in Patients With Recurrent Ovarian Cancer

Role: collaborator

NCT02384850Phase 1Terminated

Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer

Role: lead

NCT02249091Phase 2Completed

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Role: lead

NCT03795272Phase 2Withdrawn

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

Role: collaborator

NCT03466827Phase 2Unknown

Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma

Role: collaborator

All 5 trials loaded